Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Core Viewpoint - The conference call discusses the top line results of the Phase III INDIGO trial for obexelimab, aimed at treating immunoglobulin G4-related disease (IgG4-RD) [2]. Group 1: Company Overview - Zenas Biopharma is conducting a registrational Phase III trial for obexelimab, which targets IgG4-RD [2]. - The call is being recorded and will be available for replay on the company's website [1]. Group 2: Forward-Looking Statements - The presentation includes forward-looking statements regarding expectations or predictions of future events and performance [3]. - These statements are subject to risks and uncertainties that may lead to actual results differing from those anticipated [3].